National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the commonest causes of hospital acquired infections. Vancomycin is the drug of choice for the treatment of MRSA. Increase in Minimum inhibitory concentration (MIC) of Vancomycin has been observed in both Methicillin sensitive and resistant Staphylococcal isolates. In critically ill patients, Vancomycin has become a poor therapeutic antibiotic whereas; Linezolid has emerged as an alternative drug in treating such patients. This study was undertaken to determine the sensitivity pattern among clinical isolates of Staphylococcus aureus (S. aureus) to Vancomycin and Linezolid, in order to formulate a better treatment.100 S. aureuswere isolated from various clinical specimens. Antibiotic sensitivity testing was performed by Kirby Bauer disc diffusion method and MICs of Vancomycin and Linezolid were determined by E-test following CLSI guidelines. Out of 100 S. aureus isolated, 68 were MRSA strains. Among 68 strains of MRSA for which MIC levels of Vancomycin 4 µg/ml, 2µg/ml and 1 µg/ml were 4, 27, and 37 respectively. Similarly, out of total MRSA strains MIC levels of Linezolid 4 µg/ml, 2µg/ml and 1 µg/ml were 1, 25, and 42 respectively. All 100 strains showed similar in-vitro efficacy for Vancomycin and Linezolid by Kirby Bauer disc diffusion method, but the number of strains with higher ranges of MICs of Vancomycin were more as compared to those which had higher ranges of MICs for Linezolid. Hence we suggest that Linezolid can be used as an alternative for the treatment of MRSA.
Citations |
 |
 |
 |
 |
